ABCELLERA BIOLOGICS INC (ABCL)

CA00288U1066 - Common Stock

3.42  -0.01 (-0.29%)

After market: 3.42 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (6/12/2024, 3:30:00 PM)

After market: 3.42 0 (0%)

3.42

-0.01 (-0.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-37.02%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.01B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABCL Daily chart

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 495 full-time employees. The company went IPO on 2020-12-11. The company is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. The company provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The firm uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The firm partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. The company generates a range of diverse antibodies with immunization strategies and single-cell screening.

Company Info

ABCELLERA BIOLOGICS INC

2215 Yukon Street

Vancouver BRITISH COLUMBIA

P: 16045599005

Employees: 495

Website: https://www.abcellera.com/

ABCL News

News Image15 days ago - AbCellera Biologics Inc.AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
News Imagea month ago - InvestorPlace3 Stock Gems Hiding in the Nasdaq

If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks.

News Imagea month ago - The Motley FoolAbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2024.

News Imagea month ago - InvestorPlaceABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024

ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Imagea month ago - AbCellera Biologics Inc.AbCellera Reports Q1 2024 Business Results
News Imagea month ago - AbCellera Biologics Inc.AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

ABCL Twits

Here you can normally see the latest stock twits on ABCL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example